Abstract
DNA methylation is a common mode of gene silencing in cancer, and MDS remains the poster child for a disease in which targeting the DNMT enzymes leads to clinical benefit.1-4 However, some important questions remain unanswered, 2 of which are directly addressed in this issue of Blood by Figueroa and colleagues5: What pivotal gene sets are silenced by DNA methylation in MDS and de novo AML, a question that begs a reference to the patterns of normal marrow cells on a genome-wide scale, and what global changes in DNA methylation can be achieved when treating patients with DNMT inhibitors?
Original language | English (US) |
---|---|
Pages (from-to) | 3363-3364 |
Number of pages | 2 |
Journal | Blood |
Volume | 114 |
Issue number | 16 |
DOIs |
|
State | Published - 2009 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology